Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. ~~09/533,798~~ 10/774,176
		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1642~~

OIPE JC29 MAY 13 2004 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
MD	A1	5,118,672	06/92	Schinazi et al.	514	47	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
MD	A2	99/15684	04/99	WIPO				
	A3	99/15683	04/99	WIPO				
	A4	89/07947	09/89	WIPO				
MD	A5	92/03568	03/92	WIPO				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

MD	A6	Guschlbauer et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic Characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933
	A7	Schibahara et al., "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403
	A8	Gershon et al, "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene Shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989
	A9	Weir et al., "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous Frameshift mutations" J. Virol. 46:530 ,1983
	A10	Esposito et al., "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984
	A11	Kilpatrick et al., "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985
	A12	Binns et al., "Comparison of a conserved region in fowlpox virus and vaccinia virus gnomes and the translocation of the fowlpox virus thymidine kinase gene"J. Gen. Virol 69:1275, 1988
	A13	Schnitzlein et al., "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988
MD	A14	Fathi et al., "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97-105, 1986

EXAMINER	DATE CONSIDERED
/Marianne DiBrino/	09/22/2006

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	APPLICANT Miles William CARROLL et al. 10/774,176	
	FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1643~~

MAY 13 2004 PTO/SB/08 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

MD	A15	Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973
	A16	Straibinger et al., "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983
	A17	Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 60-89, 1990
	A18	Matthias et al., "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418
	A19	Wootton & Federhen, "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163
	A20	Myers et al., "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324
	A21	Starzynska et al., "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902
	A22	Starzynska et al., "The expression of 5T4 antigen in colorectal and gastic carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869
	A23	Hobbs et al., "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'deoxyribose"1973 Biochemistry 12:5138
	A24	Starzynska et al., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun;10(6)479-484
	A25	Carsberg et al., "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92
MD	A26	Yewdell et al., "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31
	A27	~~Calvert et al., "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian~~ reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993
	A28	~~Carroll et al., "Construction and characterization of a triple recombinant vaccinia virus encoding B7-1,~~ interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887
	A29	~~Two bright new faces in gene therapy" Nature Biotechnology 1998 14, 556~~

EXAMINER	DATE CONSIDERED
/Marianne DiBrino/	09/22/2006

- **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. ~~09/533,798~~ 10/774,176
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1643~~

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A30	~~Pieken et al., "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991~~ Science 253:314-317
MD	A31	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175
	A32	~~Fu et al., "An endoplasmic reticulum targeting signal sequence enhances the immunogenicity of an~~ immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81
	A33	~~Schodel et al., "hepatitis B virus core and e antigen: Immune recognition and use as a vaccine carrier moiety"~~ 1996 Intervirology 39:104-10
	~~A34~~	~~Wolff and Trubetskoy, "The cambrian period of nonviral gene delivery" 1998 nature Biotechnology 16:421-~~ 423
	A35	~~Taylor et al., "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65)~~ in non-avian species" 1995 Vaccine 13:539-549
	~~A36~~	~~Stannard et al., "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin"~~ J. Gen. Virol. 1998 79:1637-46
	A37	~~Mackett et al., "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-~~ 7419
	A38	~~Upton et al, "Identification and nucleotide sequence of the thymidine kinase gene of shope fibroma virus" J.~~ Virology 60:920, 1986
	~~A39~~	Boyle et al, "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine ~~kinases~~" Virology 156:355-365, 1987
	A40	~~Lewis et al, "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J~~ 11:3053-3058
	A41	~~Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not for the human~~ immunodeficiency virus" 1994 J. Virol. 68:510-516
	A42	~~Mackett et al. "General method for production and selection of infectious vaccinia virus recombinants~~ expressing foreign genes" 1984, J. Virol. 49:857-864

EXAMINER	/Marianne DiBrino/	DATE CONSIDERED	09/22/2006

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. ~~09/532,796~~ 10/774,176
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1643~~

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A43	~~Hruby et al, "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene"~~ PNAS 80:3411-3415, 1983
	A44	~~Lytvyn et al "Comparison of the thymidine kinase genes from three entompoxiruses" J. Gen Virol~~ 73:3235-3240 1992
	~~A45~~	~~Smith et al., "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154~~
	A46	~~Jenkins et al, "Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus"~~ AIDS Research and Human Retroviruses 7:991-998, 1991
	~~A47~~	~~Taylor et al, "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-~~ 503, 1988
	A48	~~Spheper et al and Boursnell et al, "Insertion of the fusion gene from newcastle disease virus into a non~~ essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by The recombinant" 1990 J. Gen. Virol. 71:621-628
	A49	~~Nakano et al, "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci.~~ USA 79, 1593-1596, 1982
	A50	~~Chakrabarti et al., "Vaccinia virus expression vector: coexpression of β-galactosidase provides visual~~ screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985
	A51	~~Wigler et al, "Transformation of mammalian cells with genes from procaryotes and eucaryotes" Cell 777-785,~~ 1979
	~~A52~~	~~Graessmann et al, "Microinjection of tissue culture cells" Meth. Enzymology 101, 482-492, 1983~~
	A53	~~Franke et al, "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia~~ virus recombinants" Mol Cell biol 1918-1924, 1985
	A54	~~Altenburger, W., Suter, C.P. and Altenburger J., "Partial deletion of the human host range gene in the~~ attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27

EXAMINER	DATE CONSIDERED
/Marianne DiBrino/	09/22/2006

• **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. ~~09/333,798~~ 10/744,176
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1643~~

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A55	~~Neumann et al., "Gene transfer into mouse lyoma cell by electroporation in high electric fields" EMBO J. 1,~~ 841-845, 1982
	A56	~~Schaffner, "Direct transfer of cloned genes form bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA~~ 77,2163-2167, 1980
	A57	~~Nestle FO et al, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat.~~ Med. 1998 Mar;4(3):328-32
	~~A58~~	~~Altschul et al, "Issues in searching molecular sequence database" 1994 Nature Genetics 6:119-129~~
	A59	~~Carroll & Moss, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus:~~ propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211
	A60	~~Kim GJ et al., "Dendritic cell infected with poxviruses encoding Mart-1/melan-a sensitive T Lymphocytes in~~ vitro" J. Immunother, 1997 Jul;20(4):276-86
	A61	~~Schneider et al., "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of~~ malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402
	A62	~~Chakrabarti et al, "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997~~ Biotechniques 23:1094-1097
	A63	~~Wyatt et al., "Development of replication-deficient recombinant vaccinia virus vaccine effective against~~ parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458
	A64	~~Sutter et al, "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain~~ Of vaccinia virus stimulates protective immunity in mice to influenza virus", 1994 Vaccine 12:1032-1040
	A65	~~Carroll and Moss "*E. coli* β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995~~ Biotechniques 19:352-355
	A66	~~Hirsch et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)~~ infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752

EXAMINER	/Marianne DiBrino/	DATE CONSIDERED	09/22/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. ~~09/533,708~~ 10/774,176
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644 ~~1643~~

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A67	~~Sutter and Moss, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl.~~ Acad Sci USA 89:10847-10851
	A68	~~Bronte et al., "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model~~ recombinant poxvirus tumor vaccine" 1997, Proc. Natl Acad Sci USA 94(7):3183-3188
	A69	~~Wyatt et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient~~ gene expression in mammalian cells" 1995 Virology 210:202-205
MD	A70	Carroll et al., "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model" 1997 Vaccine, 15:387-394
	A71	~~Sutter et al, "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase"~~ 1995 FEBS lett. 371:9-12
	A72	~~Overwijk et al. "gp100/pmel 17 is a murine tumor rejectio antigen-induction of "Self"- reactive, tumoricidal T~~ cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286
	A73	~~Hola N. and Stern PL "Isolation and characterization of 5T4, a tumor-associated antigen", (1999) Int. J.~~ Cancer 45(1): 179-184

EXAMINER /Marianne DiBrino/	DATE CONSIDERED 09/22/2006

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE CITATION	078883/0120	~~09/533,790~~ 10/774,176
	APPLICANT: Miles William CARROLL and Kevin Alan MYERS	
Date Submitted to PTO: September 6, 2000	FILING DATE: March 24, 2000	GROUP ART UNIT: 1644 ~~1642~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
MD	A1	EP-A-0198328	04/02/86	Europe				
MD	A2	EP-A-0110385	11/29/83	Europe				

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
/Marianne DiBrino/	09/22/2006

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/774,176
Filing Date	February 6, 2004
First Named Inventor	Carroll, Miles W.
Art Unit	1644
Examiner Name	Marianne NMN Dibrino
Attorney Docket Number	021911-000510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
MD	AU	PCT	WO97/19183	A2	05/29/1997	Glaxo Group Limited		☐
	AV							☐
	AW							☐
	AX							☐
	AY							☐
	AZ							☐
	BA							☐
	BB							☐

Examiner Signature	/Marianne DiBrino/	Date Considered	09/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/774,176
Filing Date	February 6, 2004
First Named Inventor	Carroll, Miles W.
Art Unit	1644
Examiner Name	Marianne NMN Dibrino
Attorney Docket Number	021911-000510US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
MD	BC	CORREALE, Pierpaolo, et al. "Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide", *The Journal of Immunology* (1998) 161:3186-3194	
	BD	HODGE, James W., et al. "A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate", *Int. J. Cancer* (1995) 63:213-237	
	BE	HOLE, N., et al. "A 72 kD trophoblast glycoprotein defined by a monoclonal antibody", *Br. J. Cancer* (1998) 57:239-246	
	BF	IRVINE, Kari R., et al. "Synthetic Oligonucleotide Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic CTL", *The Journal of Immunology* (1995) *154:4651-4657*	
	BG	JACKSON, Ronald J., et al. "Infertility in Mice Induced by a Recombinant Ectromelia Virus Expressing Mouse Zona Pellucida Glycoprotein 3", *Biology of Reproduction* (1998) 58:152-159	
	BH	KASS, Erik, et al. "Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus", *Cancer Research* (1999) 59:676-683	
	BI	ROSATO, Antonio, et al. "CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific Antigen P815A", *Human Gene Therapy* (1997) 8:1451-1458	
	BJ	SANDA, Martin G., et al. "Recombinant Vaccinia-PSA (Prostvac) Can Induce a Prostate-Specific Immune Response in Androgen-Modulated Human Prostate Cancer", *Urology* (1999) 53:260-266	
	BK	SOUTHALL, P.J., et al. "Immunohistological distribution of 5T4 antigen in normal and malignant tissues", *Br. J. Cancer* (1990) 61:89-95	
	BL	TSANG, Kwong Y., et al. "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine", *J. Natl. Cancer Inst.* (1995) 87(13):982-990	
MD	BM	WANG, Rong-Fu "Tumor Antigens Discovery: Perspectives for Cancer Therapy", *Molecular Medicine* (1997) 3(11):716-731	

Examiner Signature	/Marianne DiBrino/	Date Considered	09/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.